Skip to main content
SpringerLink
Log in

Radiolabeling and biological evaluation of 125I-Necitumumab for EGFR-targeted SPECT imaging

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Radiolabeled epidermal growth factor receptor (EGFR) targeted antibody could be used for imaging EGFR expressing cancer. In this study, the SPECT probe 125I-Necitumumab were synthesized and evaluated for SPECT imaging of non-small cell lung cancer (NSCLC). In vivo biodistribution study indicated that 125I-Necitumumab was cleared rapidly in most organs and tissues. Though the tumor expressed a relatively high level of EGFR, however SPECT images showed no obvious uptake in the tumors. Therefore, we considered that 125I-Necitumumab was not suitable for EGFR-targeted NSCLC SPECT imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Availability of data and material

Please contact the author for data requests.

References

  1. Mulatero C, Lal R, Jewitt K, Tolley C, Wells J, Arbuckle R, Lloyd A, Brezier J, Devlin D (2015) Qualitative interviews to provide in-depth understanding of the impact of non-small cell lung cancer (NSCLC) and its treatment on Of the lives of patients and their families/caregivers. Value Health 18:A469–A469

    Article  Google Scholar 

  2. Kupis WR, Rudzinski PM, Orlowski TM (2007) P3-236: tumor size and 5-year survival rate in surgically treated patients with pN0M0 NSCLC. J. Thorac. Oncol. 2(Supplement 4):S780

    Article  Google Scholar 

  3. Essam HM (2007) Integrated PET/CT in imaging of non-small cell lung cancer. J Egypt Natl Canc Inst 19:263–274

    Google Scholar 

  4. Buckstein M, Yip R, Yankelevitz DF, Henschke CI, Rosenzweig K (2014) Radiation therapy for stage I lung cancer detected on computed tomography screening: results from the international early lung cancer action program. Int J Radiat Oncol 3:153–157

    Article  Google Scholar 

  5. Dutu T, Michiels S, Fouret P, Penaultllorca F, Validire P, Benhamou S, Taranchon E, Morat L, Grunenwald T, Le Chevalier L, Sabatier, Soria J-C (2005) Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 16:1906–1914

    Article  CAS  Google Scholar 

  6. Lu XM, Wang C, Li X, Gu PL, Jia LN, Zhang L (2019) Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer. Bioorg Med Chem 27:545–551

    Article  CAS  Google Scholar 

  7. Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Bao C, Bassi R, Prewett M, Tonra JR (2012) Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genom Proteom 9(2):77–92

    CAS  Google Scholar 

  8. Cai W, Chen K, He L, Cao Q, Koong A, Chen X (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol I 34:850–858

    Article  CAS  Google Scholar 

  9. Shih BB, Chang YF, Cheng CC, Yang HJ, Chang KW, Ho AS, Lin HC, Yeh C, Chang CC (2017) SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft. J Chin Med Assoc 80:766–773

    Article  Google Scholar 

  10. Cw MDHVO, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, Mulder ER, Schuit RC, Boellaard R, Hoekstra OS (2015) 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget 6:30384–30393

    Google Scholar 

  11. Liu Y, Jin C, Yang S, Jia B, Wang F, Liu Z (2010) 125I/111In labeled anti-EGFR monoclonal antibody panitumumab: preparation and biodistribution evaluation in normal mice. J Nucl Radiochem 32:362–368 (in Chinese)

    Google Scholar 

  12. Genova C, Hirsch FR (2016) Clinical potential of necitumumab in non-small cell lung carcinoma. Oncotargets Ther 9:5427–5437

    Article  CAS  Google Scholar 

  13. Greillier L, Tomasini P, Barlesi F (2015) Necitumumab for non-small cell lung cancer. Expert Opin Biol Ther 15:1231–1239

    Article  CAS  Google Scholar 

  14. Dienstmann R, Tabernero J (2010) Necitumumab a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 11:1434–1441

    CAS  PubMed  Google Scholar 

  15. Long A, Chigutsa E, Wallin J (2017) Population pharmacokinetics of necitumumab in cancer patients. Clin Pharmacokinet 56:505–514

    Article  CAS  Google Scholar 

  16. Li D, Wang C, Zhang D, Peng Y, Ren S, Li X, Zou C (2018) Preliminary application of 125I–nivolumab to detect PD-1 expression in colon cancer via SPECT. J Radioanal Nucl Chem 318:1237–1242

    Article  CAS  Google Scholar 

  17. Karmani L, Levêque P, Bouzin C, Bol A, Dieu M, Walrand S, Vander BT, Feron O, Gregoire V, Bonifazi D, Michiels C, Lucas S, Gallez B (2016) Biodistribution of 125I-labeled anti-endoglin antibody using SPECT/CT imaging: impact of in vivo deiodination on tumor accumulation in mice. Nucl Med Biol 43:415–423

    Article  CAS  Google Scholar 

  18. Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S, Närvänen A (2010) In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with In-labeled monoclonal antibodies. Nucl Med Biol 37:957–964

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shanghai Institute of Applied Physics (SINAP), Chinese Academy of Sciences, Shanghai, 201800, People’s Republic of China

    Xinmiao Lu, Lina Jia & Lan Zhang

  2. University of Chinese Academy of Sciences, Beijing, 100049, People’s Republic of China

    Xinmiao Lu

  3. Department of Nuclear Medicine, Changhai Hospital, Shanghai, 200433, China

    Xiao Li, Ye Peng, Tao Wang & Danni Li

Authors
  1. Xinmiao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ye Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Danni Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lina Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

This study was financially supported by grants from the National Nature Science Foundation of China (NSFC) under Contract No.11505269 and the Strategic Priority and Research Program of Chinese Academy of Science under Contract No. XDA02000000.

Corresponding author

Correspondence to Lina Jia.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, X., Li, X., Peng, Y. et al. Radiolabeling and biological evaluation of 125I-Necitumumab for EGFR-targeted SPECT imaging. J Radioanal Nucl Chem 323, 83–89 (2020). https://doi.org/10.1007/s10967-019-06933-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-019-06933-8

Keywords

Search

Navigation